Company:  COHERUS BIOSCIENCES, INC. (CHRS)
Form Type:  4
Filing Date:  5/19/2017 
CIK:  0001512762 
Address:  C/O DENNIS M. LANFEAR
333 TWIN DOLPHIN DR, SUITE 600
 
City, State, Zip:  REDWOOD CITY, California 94065 
Telephone:  (650) 649-3530 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$15.30  
Change: 
-0.30 (-1.92%)  
Trade Time: 
May 25  
Market Cap: 
$999.50M
Trade CHRS now with 

© 2018  
Description of Business
We are a late-stage clinical biologics platform company focused on the global biosimilar market. Biosimilars are an emerging class of protein-based therapeutics with high similarity to approved originator products on the basis of various physicochemical and structural properties, as well as safety, purity and potency. Our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our business is organized around therapeutic franchises: 1) Oncology biosimilar candidate, CHS-1701 for pegfilgrastim (Neulasta®), which has been filed for approval in Europe, and for which we expect to refile a BLA for potential approval in the United States ("U.S.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES